FrancophonIA/ELRC3.0 huggingface dataset:
English: However, the retrospective subgroup analyses performed by the MAH support the conclusion that the risks for vascular complications seemed to be reduced to a neutral level by the exclusion of patients with identified increased cardiovascular risk while anti-fracture efficacy seems to be preserved, even in the subset of patients with severe osteoporosis.
Estonian: „Inimravimite komitee jõudis aga järeldusele, et patsientidel, kelle puhul ei ole muu ravi võimalik, vähendab regulaarne jälgimine kardiovaskulaarsete haiguste välistamiseks ravimiohutuse riskihindamiskomitee tuvastatud riskide esinemist piisavalt, nii et need patsiendid saavad jätkuvalt seda ravimit võtta.”
English: Strontium ranelate, the active substance of Protelos/Osseor, is composed of two atoms of stable strontium and one molecule of ranelic acid.
Estonian: • Ravi Protelose/Osseoriga tuleb peatada, kui patsiendil tekib südame isheemiatõbi, perifeersete arterite haigus või ravimata hüpertensioon.
English: While it is agreed that the pooled postmenopausal dataset is relevant for safety evaluation, the CHMP considered that the anti-fracture efficacy should be analysed based on data from the phase 3 studies TROPOS and SOTI conducted over 3 years in a population at high risk of fractures, with fractures defined as primary endpoint.
Estonian: Euroopa Ravimiameti lõplik soovitus Protelose/Osseori kasutamise kohta põhineb randomiseeritud uuringute, kus osales ligikaudu 7500 menopausijärgses eas osteoporoosiga naist, koondandmete analüüsil.
English: Grounds for PRAC recommendation
Estonian: Lisateave ravimi kohta
English: The CHMP therefore recommended the variation of the marketing authorisations for Protelos and Osseor.
Estonian: Ravimite Protelos/Osseor müügiluba jääb kehtima, aga lisapiirangutega
English: Experts also specified that strontium ranelate should be used only in severe osteoporosis with significant fragility fracture such as hip and not “trivial” ones such as metacarpal (which was given as an example).
Estonian: • Protelost/Osseori määratakse luumurdude ennetamiseks ainult raske osteoporoosiga meestel ja menopausijärgses eas naistel, kellel on suur luumurrurisk ja keda ei saa teiste osteoporoosi raviks heaks kiidetud ravimitega ravida.
English: The postmenopausal osteoporotic (PMO) population for strontium ranelate comprises data from 7 randomised studies: 2 phase II studies CL2-004 (Meunier, 2002; NP07869) and CL2-005 (Reginster 2002; NP08511) and 5 phase III studies CL3-009 (Meunier, 2004; NP08338/NP22819), CL3-010 (Reginster 2005; NP08340/NP22824), CL3-013 (Hwang 2008; NP22514), CL3-015 (Liu 2009; NP25026), CL3-017 (NP24357).
Estonian: Tel. +44 (0)20 7418 8427 E-post: press@ema.europa.eu
English: It blocks the proteasome, which is a system within the cells that breaks down proteins when they are no longer needed.
Estonian: See blokeerib proteasoomi ehk rakusisese süsteemi, mis lagundab valke, kui neid enam ei vajata.
English: Further information on Bortezomib Fresenius Kabi can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/bortezomib-fresenius-kabi.
Estonian: Lisateave Bortezomib Fresenius Kabi kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/bortezomib-fresenius-kabi.
English: The recommended starting dose depends on the patient's height and weight.
Estonian: Soovitatav algannus sõltub patsiendi pikkusest ja kehamassist.
English: For more information on generic medicines, see the question-andanswer document here.
Estonian: Lisateave geneeriliste ravimite kohta on teabedokumendis siin.
English: • adults whose disease is getting worse after at least one other treatment and who have already had, or cannot undergo, a blood stem-cell transplant.
Estonian: • Täiskasvanud, kelle haigus süveneb pärast vähemalt üht muud raviskeemi ja kellele on vereloome tüvirakke juba siiratud või ei saa siirata.
English: Patients with moderately or severely impaired liver function should be treated with lower doses.
Estonian: Mõõduka või raske maksatalitlushäirega patsientide annus peab olema väiksem.
English: What measures are being taken to ensure the safe and effective use of Bortezomib Fresenius Kabi?
Estonian: Mis meetmed võetakse, et tagada Bortezomib Fresenius Kabi ohutu ja efektiivne kasutamine?
English: The European Medicines Agency concluded that, in accordance with EU requirements, Bortezomib Fresenius Kabi has been shown to be comparable to Velcade.
Estonian: Euroopa Ravimiamet järeldas, et vastavalt ELi nõuetele on tõendatud Bortezomib Fresenius Kabi võrreldavus ravimiga Velcade.
English: Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Velcade, and do not need to be repeated for Bortezomib Fresenius Kabi.
Estonian: Võrdlusravimiga Velcade on juba tehtud toimeaine heakskiidetud kasutamisviisi kasulikkuse ja riski uuringud ja neid ei ole vaja ravimiga Bortezomib Fresenius Kabi korrata.
English: Doses of Bortezomib Fresenius Kabi are given intermittently, with rest periods in between doses, in treatment cycles of three to six weeks depending on whether Bortezomib Fresenius Kabi is given alone or in combination with other medicines.
Estonian: Ravimit Bortezomib Fresenius Kabi manustatakse ravikuuridena, jättes annuste vahele puhkeperioodi, nii et ravikuurid kestavad 3-6 nädalat sõltuvalt sellest, kas Bortezomib Fresenius Kabit kasutatakse ainuravimina või koos muude ravimitega.
English: Bortezomib Fresenius Kabi (bortezomib)
Estonian: Bortezomib Fresenius Kabi (bortesomiib)
English: This means that Bortezomib Fresenius Kabi contains the same active substance, bortezomib, and works in the same way as a ‘reference medicine' already authorised in the EU called Velcade.
Estonian: See tähendab, et Bortezomib Fresenius Kabi sisaldab sama toimeainet, bortesomiibi, ja toimib samamoodi nagu võrdlusravim Velcade, millel juba on ELis müügiluba.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Bortezomib Fresenius Kabi have also been included in the summary of product characteristics and the package leaflet.
Estonian: Ravimi Bortezomib Fresenius Kabi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Because Bortezomib Fresenius Kabi is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Bortezomib Fresenius Kabi on geneeriline ravim, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Therefore, the Agency's view was that, as for Velcade, the benefits of Bortezomib Fresenius Kabi outweigh the identified risks and it can be authorised for use in the EU.
Estonian: Seetõttu on amet arvamusel, et nagu ka Velcade korral, ületab Bortezomib Fresenius Kabi kasulikkus sellega kaasnevad riskid ja seda võib kasutada ELis.
English: The company that markets Bortezomib Fresenius Kabi will ensure that healthcare professionals receive educational material explaining how to calculate the dose and how to prepare and administer the medicine.
Estonian: Bortezomib Fresenius Kabi turustaja annab tervishoiutöötajatele teabematerjalid, milles selgitatakse, kuidas arvutada annust ning ravimit ette valmistada ja manustada.
English: Side effects reported with Bortezomib Fresenius Kabi are carefully evaluated and any necessary action taken to protect patients.
Estonian: Ravimi Bortezomib Fresenius Kabi kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: For more information about using Bortezomib Fresenius Kabi, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet ravimi Bortezomib Fresenius Kabi kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: Why is Bortezomib Fresenius Kabi authorised in the EU?
Estonian: Miks Bortezomib Fresenius Kabi ELis heaks kiideti?
English: As for every medicine, the company provided studies on the quality of Bortezomib Fresenius Kabi.
Estonian: Nagu iga ravimi korral, esitas ettevõte ravimi Bortezomib Fresenius Kabi kvaliteedi uuringud.
English: When given into a vein, the solution is given as a three- to five-second injection through a catheter (a thin sterile tube).
Estonian: Veeni süstimisel manustatakse lahus süstena kateetri (peene steriilse vooliku) kaudu 3-5 sekundi jooksul.
English: Bortezomib Fresenius Kabi is a ‘generic medicine'.
Estonian: Bortezomib Fresenius Kabi on geneeriline ravim.
English: Bortezomib Fresenius Kabi is also used to treat mantle cell lymphoma, another blood cancer, in untreated adults who cannot have blood stem-cell transplantation.
Estonian: Ravimit Bortezomib Fresenius Kabi kasutatakse ka teist tüüpi verevähi, mantelrakulise lümfoomi raviks varem ravimata täiskasvanutel, kellele ei saa siirata vereloome tüvirakke.
English: When injected under the skin, it is given in the thigh or abdomen (belly).
Estonian: Kui ravimit süstitakse naha alla, tehakse süst reide või kõhupiirkonda.
English: What is Bortezomib Fresenius Kabi and what is it used for?
Estonian: Mis on Bortezomib Fresenius Kabi ja milleks seda kasutatakse?
English: The medicine can only be obtained with a prescription and treatment should only be started and given under the supervision of a doctor who has experience in the use of cancer medicines.
Estonian: Bortezomib Fresenius Kabi on retseptiravim ning ravi peab algama ja toimuma vähiravimite kasutamises kogenud arsti järelevalve all.
English: As for all medicines, data on the use of Bortezomib Fresenius Kabi are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse ravimi Bortezomib Fresenius Kabi kasutamise kohta pidevat järelevalvet.
English: Bortezomib Fresenius Kabi is a medicine used to treat multiple myeloma, a blood cancer, in the following groups of patients:
Estonian: Bortezomib Fresenius Kabi on ravim, mida kasutatakse hulgimüeloomi (teatud verevähk) raviks järgmistel patsiendirühmadel.
English: Other information about Bortezomib Fresenius Kabi
Estonian: Muu teave Bortezomib Fresenius Kabi kohta
English: Fresenius Kabi is only given by injection into a vein or under the skin.
Estonian: Ravimit Bortezomib Fresenius Kabi manustatakse üksnes süstena veeni või naha alla.
English: There was no need for ‘bioequivalence' studies to investigate whether Bortezomib Fresenius Kabi is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood.
Estonian: Bioekvivalentsust, st kas Bortezomib Fresenius Kabi imendub organismis samamoodi kui võrdlusravim, et saavutada toimeaine sarnane sisaldus veres, ei olnud vaja uurida.
English: This is because when Bortezomib Fresenius Kabi is given by injection into a vein the active substance is delivered straight into the bloodstream.
Estonian: Seda ei olnud vaja, sest kui ravimit Bortezomib Fresenius Kabi manustatakse süstena veeni, satub toimeaine otse vereringesse.
English: For mantle cell lymphoma, Bortezomib Fresenius Kabi is used in combination with rituximab, cyclophosphamide, doxorubicin and prednisone.
Estonian: Mantelrakulise lümfoomi ravis kasutatakse ravimit Bortezomib Fresenius Kabi koos rituksimaabi, tsüklofosfamiidi, doksorubitsiini ja prednisooniga.
English: Bortezomib Fresenius Kabi is available in vials (3.5 mg) as a powder to be made up into a solution for injection.
Estonian: Ravimit Bortezomib Fresenius Kabi turustatakse viaalides (3,5 mg) süstelahuse pulbrina.
English: In these patients, Bortezomib Fresenius Kabi is used in combination with melphalan and prednisone;
Estonian: Ravimit Bortezomib Fresenius Kabi kasutatakse neil patsientidel koos melfalaani ja prednisooniga.
English: In this group of patients, Bortezomib Fresenius Kabi is used in combination with dexamethasone, or with dexamethasone plus thalidomide;
Estonian: Selles patsiendirühmas kasutatakse ravimit Bortezomib Fresenius Kabi koos deksametasooniga või koos deksametasooni ja talidomiidiga.
English: Additionally, when Bortezomib Fresenius Kabi is given under the skin, the active substance in both products, which have the same composition, is expected to be absorbed in the same way.
Estonian: Kui ravimit manustatakse süstena naha alla, imendub mõlema sama koostisega ravimi toimeaine eeldatavasti samal viisil.
English: The active substance in Bortezomib Fresenius Kabi, bortezomib, is a proteasome inhibitor.
Estonian: Bortezomib Fresenius Kabi toimeaine bortesomiib on proteasoomiinhibiitor.
English: How has Bortezomib Fresenius Kabi been studied?
Estonian: Kuidas ravimit Bortezomib Fresenius Kabi uuriti?
English: An overview of Bortezomib Fresenius Kabi and why it is authorised in the EU
Estonian: Ülevaade ravimist Bortezomib Fresenius Kabi ja ELis müügiloa väljastamise põhjendus
English: Bortezomib Fresenius Kabi is either used on its own in these patients or in combination with pegylated liposomal doxorubicin or dexamethasone.
Estonian: Neil patsientidel kasutatakse ravimit Bortezomib Fresenius Kabi kas ainuravimina või koos pegüleeritud liposomaalse doksorubitsiini või deksametasooniga.
English: How does Bortezomib Fresenius Kabi work?
Estonian: Kuidas Bortezomib Fresenius Kabi toimib?
English: How is Bortezomib Fresenius Kabi used?
Estonian: Kuidas ravimit Bortezomib Fresenius Kabi kasutatakse?
English: They will also advise you how to stop treatment if necessary.
Estonian: Samuti annavad nad teile nõu, kuidas ravi vajadusel peatada.
English: If it does, the skin could be damaged.
Estonian: Kui see juhtub, võib nahk saada kahjustatud.
English: Also your blood pressure can become too low.
Estonian: Samuti võib teie vererõhk langeda liiga madalale.
English: The procedure given below should be closely followed.
Estonian: Allpool toodud protseduure tuleb rangelt järgida.
English: It is also a potent vasodilator.
Estonian: See on ka tugev vasodilataator.
English: This is because your doctor needs to monitor you and find the best dose for you.
Estonian: See on sellepärast, et teie arst tahab teid jälgida ja leida teie jaoks parima annuse.
English: Other medicines and Flolan
Estonian: Muud ravimid ja Flolan
English: Your doctor will decide how much Flolan is right for you.
Estonian: Teie arst otsustab, kui palju Flolan'i on teie jaoks õige kogus.
English: Investigations Unknown
Estonian: Uuringud Teadmata
English: A risk to the breastfeeding child cannot be excluded.
Estonian: Riski rinnaga toidetavale imikule ei saa välistada.
English: The safety and efficacy of epoprostenol in children younger than 18 years have not yet been established.
Estonian: Epoprostenooli ohutust ja efektiivsust ei ole alla 18-aastastel lastel veel tõestatud.
English: Flolan is not a conventional anticoagulant.
Estonian: Flolan ei ole tavapärane antikoagulant.
English: This medicinal product must not be mixed with other medicinal products except those mentioned in section 4.2.
Estonian: Seda ravimit ei tohi segada teiste ravimitega, väljaarvatud lõigus 4.2 toodud ravimitega.
English: • if you have heart failure.
Estonian: kui teil on südamepuudulikkus.
English: Adverse events are listed below by system organ class and frequency.
Estonian: Järgnevalt toodud kõrvaltoimed on loetletud organsüsteemi klassi ja esinemissageduse järgi.
English: • You have more frequent, or longer periods of bleeding.
Estonian: - Kui teil on sagedamini või pikemat aega verejooks.
English: Mean systemic arterial pressure was not significantly different between the two groups (-4.33 vs. -3.05 mm Hg).
Estonian: Keskmine süsteemne arteriaalne rõhk ei erinenud oluliselt gruppide vahel (-4,33 vs -3,05 mm Hg).
English: Your first treatment will be given to you in a hospital.
Estonian: Esimest korda manustatakse teile ravimit haiglas.
English: Flolan can cause your heart to beat faster or slower.
Estonian: Flolan võib panna teie südame lööma kiiremini või aeglasemalt.
English: Following the administration of radiolabelled epoprostenol to humans, at least 16 metabolites were found, 10 of which were structurally identified.
Estonian: Pärast radiomärgistatud epoprostenooli manustamist inimestele leiti vähemalt 16 metaboliiti, neist 10 metaboliidil tehti kindlaks struktuur.
English: Local infection*
Estonian: Paikne infektsioon*
English: If you think any of these apply to you, don't take Flolan until you have checked with your doctor.
Estonian: Kui te arvate, et midagi sellest kehtib teie puhul, ärge kasutage Flolan'i, kuni teie arst pole teid kontrollinud.
English: It is important that the medicine does not leak out of the vein into the surrounding tissue.
Estonian: On oluline, et ravim ei lekiks veenist välja ümbritsevatesse kudedesse.
English: 4.6 Fertility, pregnancy,and lactation
Estonian: 4.6 Fertiilsus, rasedus ja imetamine
English: Do not use this medicine after the expiry date which is stated on the label.
Estonian: Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud etiketil.
English: The liquid does not contain a preservative.
Estonian: Vedelik ei sisalda säilitusaineid.
English: Frequencies are defined as follows: very common ≥1/10 (≥10%); common ≥1/100 and <1/10 (≥1% and <10%); uncommon ≥1/1000 and <1/100 (≥0.1% and <1%); rare ≥1/10,000 and <1/1000 ( ≥0.01% and <0.1%); very rare <1/10,000 (< 0.01%) and not known (cannot be estimated from the available data).
Estonian: Kokkuleppeliselt tuuakse kõrvaltoimete esinemissagedus järgmiselt: väga sage ≥1/10 (≥10%), sage ≥1/100 ja <1/10 (≥1% ja <10%), aeg-ajalt ≥1/1000 ja <1/100 (≥0,1% ja <1%), harv ≥1/10000 ja <1/1000 (≥0,01% ja <0,1%), väga harv <1/10000 (<0,01%), teadmata (ei saa hinnata olemasolevate andmete alusel).
English: If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine as your symptoms could worsen during pregnancy.
Estonian: Kui te olete rase või imetate, arvate end olevat rase või kavatsete rasestuda, pidage enne selle ravimi kasutamist nõu oma arsti või apteekriga, kuna teie sümptomid võivad raseduse käigus halveneda.
English: For a full list of excipents, see section 6.1
Estonian: Abiainete täielik loetelu vt lõik 6.1
English: However, 9 of 27 epoprostenol dialyses were unsuccessful following multiple attempts.
Estonian: Siiski oli 9 epoprostenooli dialüüsi 27st ebaedukad, vaatamata mitmele katsele.
English: Anxiety, nervousness
Estonian: Ärevus, närvilisus
English: • High risk - having had within 3 days prior to dialysis an active bleed that stopped at the pre-dialysis phase; or having incurred surgical or traumatic wounds within 3 days prior to dialysis
Estonian: • Kõrge risk - aktiivne veritsus 3 päeva jooksul enne dialüüsi, mis peatus predialüüsi faasis; või saadud kirurgilised või traumaatilised haavad 3 päeva jooksul enne dialüüsi
English: The amount you are given is based on your body weight, and your type of illness.
Estonian: Manustatav kogus põhineb teie kehakaalul ja haiguse tüübil.
English: If you have been fitted with a ‘line' into a vein it is very important to keep this area clean, otherwise you could get an infection.
Estonian: Kui teie veeni on paigaldatud kanüül, on äärmiselt oluline hoida seda piirkonda puhtana, vastasel juhul võib teil tekkida infektsioon.
English: The infusion should be stopped at the end of dialysis.
Estonian: Infusioon tuleb dialüüsi lõppedes peatada.
English: What Flolan looks like and contents of the pack
Estonian: Kuidas Flolan välja näeb ja pakendi sisu
English: Your dose may need to be reduced or your infusion stopped.
Estonian: Teie annust võib olla tarvis vähendada või infusioon lõpetada.
English: Pharmacotherapeutic group: Antithrombotic Agents; Platelet aggregation inhibitors excl. heparin, ATC code: B01AC09
Estonian: Farmakoterapeutiline rühm: antitrombootilised ained; trombotsüütide agregatsiooni inhibiitorid, väljaarvatud hepariin; ATC-kood: B01AC09
English: This procedure should be conducted in a hospital with adequate resuscitation equipment.
Estonian: Seda protseduuri tohib läbi viia ainult haiglas, kus on käepärast elustamisvahendid.
English: Using Flolan at home (only for treatment of Pulmonary Arterial Hypertension) If you are treating yourself at home, your doctor or nurse will show you how to prepare and use Flolan.
Estonian: Flolan'i kasutamine kodus (ainult pulmonaarse arteriaalse hüpertensiooni raviks) Kui te ravite end kodus, näitab teie arst või meditsiiniõde teile, kuidas Flolan'i ette valmistada ja kasutada.
English: Flolan is a potent pulmonary and systemic vasodilator.
Estonian: Flolan on tugev pulmonaalne ja süsteemne vasodilataator.
English: Only this concentrated solution is suitable for further dilution prior to use.
Estonian: Ainult selline kontsentreeritud lahus sobib edasiseks lahjendamiseks enne kasutamist.
English: It is very important that you follow all of their instructions carefully.
Estonian: On väga tähtis, et te järgiksite kõiki oma arsti ja meditsiiniõe juhiseid hoolikalt.
English: If you have any of the liquid left over, it must be thrown away.
Estonian: Kui teil jääb mingi kogus vedelikku järele, tuleb see ära visata.
English: Talk to your doctor or pharmacist or nurse about any other side effects, including those not listed in this leaflet.
Estonian: Rääkige oma arstile, apteekrile või meditsiiniõele kõigist teistest kõrvaltoimetest, s.h ka nendest, mida ei ole selles infolehes loetletud.
English: This may be followed by blistering and shedding of the skin.
Estonian: Sellele võib järgneda villide teke ja naha koorumine.
English: Reproductive studies in animals have shown no effects on fertility (see section 5.3).
Estonian: Reproduktsiooniuuringud loomadega ei ole toimet fertiilsusele näidanud (vt lõik 5.3).
English: Given the absence of alternative medicines, epoprostenol can be used in those women who choose to continue their pregnancy, despite the known risk of pulmonary arterial hypertension during pregnancy.
Estonian: Alternatiivsete ravimite puudumise tõttu võib epoprostenooli kasutada nendel rasedatel, kes otsustavad raseduse säilitamise kasuks, vaatamata teadaolevale arteriaalse pulmonaalse hüpertensiooniga seotud riskile raseduse ajal.
English: 6.6 Special precautions for disposal and other handling Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Estonian: 6.6 Erihoiatused ravimi hävitamiseks ja käsitsemiseks Kasutamata ravimpreparaat või jäätmematerjal tuleb hävitada vastavalt kohalikele nõuetele.
English: Long-term continuous infusion:
Estonian: Pikaajaline püsinfusioon:
English: In general, the need for increases in dose from the initial long-term dose should be expected over time.
Estonian: Üldiselt võib aja jooksul ette näha annuste suurendamise vajadust esialgsest pikaajalisest annusest.
English: Epoprostenol potentiates the anticoagulant activity of heparin by approximately 50%, possibly reducing the release of heparin neutralising factor.
Estonian: Epoprostenool potentseerib hepariini antikoaguleerivat toimet umbes 50%, võimalik, et vähendades hepariini neutraliseeriva faktori vabanemist.
English: Solvent for parenteral use:
Estonian: Lahusti parenteraalseks kasutamiseks:
English: What Flolan is and what it is used for
Estonian: Mis ravim on Flolan ja milleks seda kasutatakse
English: Once Flolan powder has been dissolved, and diluted, it should ideally be used immediately.
Estonian: Kui Flolan'i pulber on lahustatud ja lahjendatud, tuleb see ideaalis koheselt ära kasutada.
English: Improvements were apparent in some patients at the end of the first week of therapy.
Estonian: Paranemisnähte täheldati mõnel patsiendil esimese ravinädala lõpus.
English: • You feel dizzy or feel faint, especially on standing.
Estonian: - Kui te tunnete pearinglust või minestamistunnet, eriti püsti seistes.
English: Those patients who continued to bleed were evaluated for changes in bleeding severity.
Estonian: Neid patsiente, kellel esines jätkuvalt veritsus, uuriti veritsuse raskuse osas.